CoChat

Understanding migraine: Potential role of neurogenic inflammation

Open access
Malhotra, Rakesh · 2016 · Annals of Indian Academy of Neurology
Cited by 162

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Neurogenic inflammation, a well-defined pathophysiologial process is characterized by the release of potent vasoactive neuropeptides, predominantly calcitonin gene-related peptide (CGRP), substance P (SP), and neurokinin A from activated peripheral nociceptive sensory nerve terminals (usually C and A delta-fibers). These peptides lead to a cascade of inflammatory tissue responses including arteriolar vasodilation, plasma protein extravasation, and degranulation of mast cells in their peripheral target tissue. Neurogenic inflammatory processes have long been implicated as a possible mechanism involved in the pathophysiology of various human diseases of the nervous system, respiratory system, gastrointestinal tract, urogenital tract, and skin. The recent development of several innovative experimental migraine models has provided evidence suggestive of the involvement of neuropeptides (SP, neurokinin A, and CGRP) in migraine headache. Antidromic stimulation of nociceptive fibers of the trigeminal nerve resulted in a neurogenic inflammatory response with marked increase in plasma protein extravasation from dural blood vessels by the release of various sensory neuropeptides. Several clinically effective abortive antimigraine medications, such as ergots and triptans, have been shown to attenuate the release of neuropeptide and neurogenic plasma protein extravasation. These findings provide support for the validity of using animal models to investigate mechanisms of neurogenic inflammation in migraine. These also further strengthen the notion of migraine being a neuroinflammatory disease. In the clinical context, there is a paucity of knowledge and awareness among physicians regarding the role of neurogenic inflammation in migraine. Improved understanding of the molecular biology, pharmacology, and pathophysiology of neurogenic inflammation may provide the practitioner the context-specific feedback to identify the novel and most effective therapeutic approach to treatment. With this objective, the present review summarizes the evidence supporting the involvement of neurogenic inflammation and neuropeptides in the pathophysiology and pharmacology of migraine headache as well as its potential significance in better tailoring therapeutic interventions in migraine or other neurological disorders. In addition, we have briefly highlighted the pathophysiological role of neurogenic inflammation in various other neurological disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/0972-2327.182302

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 81

  1. Smitherman, 2013, The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies, Headache, 427
  2. Wolff HG. Headache and Other Head Pain. New York: Oxford University Press; 1963.
  3. Buzzi, 2005, The pathophysiology of migraine: Year 2005, J Headache Pain, 105
  4. Burgos-Vega, 2015, Meningeal afferent signaling and the pathophysiology of migraine, Prog Mol Biol Transl Sci, 537
  5. Bayliss, 1901, On the origin from the spinal cord of the vaso-dilator fibers of the hind limb, and on the nature of these fibers, J Physiol, 173
  6. Geppetti, 2012, Antidromic vasodilatation and the migraine mechanism, J Headache Pain, 103
  7. Olivar, 2000, Neurogenic vasodilation in rabbit basilar isolated artery: Involvement of calcitonin-gene related peptide, Eur J Pharmacol, 61
  8. Miyoshi, 1995, Calcitonin gene-related peptide activates the K+ channels of vascular smooth muscle cells via adenylate cyclase, Basic Res Cardiol, 332
  9. Bellamy, 2006, Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons, Eur J Neurosci, 2057
  10. Gibbins, 1985, Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs, Neurosci Lett, 125
  11. Tam, 2004, The assessment of vasoactive properties of CGRP and adrenomedullin in the microvasculature: A study using in vivo and in vitro assays in the mouse, J Mol Neurosci, 117
  12. Hunt SP, O'Brien JA, Palmer JA. Role of substance P in nociception, analgesia, and aggression. In: Wood JN, editor. Molecular Basis of Pain Induction. New York: John Wiley & Sons; 2000. p. 209-60.
  13. Durham, 2004, CGRP-receptor antagonists — a fresh approach to migraine therapy?, N Engl J Med, 1073
  14. van, 1997, Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors, Neurosci Biobehav Rev, 649
  15. Zagami, 1990, Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides, Neuropeptides, 69
  16. Goadsby, 2004, Vasoactive peptide release in the extracerebral circulation of humans during migraine headache, Ann Neurol, 183
  17. Regoli, 1994, Receptors and antagonists for substance P and related peptides, Pharmacol Rev, 551
  18. Gasporovic, 1964, Contribution to the theory that substance P has a transmitter role in sensitive pathway, Med Exp Int J Exp Med, 303
  19. Battaglia, 1988, Coexistence of glutamate and substance P in dorsal root ganglion neurons of the rat and monkey, J Comp Neurol, 302
  20. Liu, 1997, NMDA-receptor regulation of substance P release from primary afferent nociceptors, Nature, 721
  21. Rosa, 2013, The role of histamine in neurogenic inflammation, Br J Pharmacol, 38
  22. Williamson, 1997, Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat, Cephalalgia, 518
  23. Alvaro, 2007, Neurokinin 1 receptor antagonists — current prospects, Curr Opin Drug Discov Devel, 613
  24. Hoyer, 1997, 5-HT receptor classification and nomenclature: Towards a harmonization with the human genome, Neuropharmacology, 419
  25. Johnson, 1998, Serotonin in migraine: Theories, animal models and emerging therapies, Prog Drug Res, 219
  26. Durham, 1997, Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation, J Neurosci, 9545
  27. Buzzi, 1990, The antimigraine drug, sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura matter, Br J Pharmacol, 202
  28. Cutrer, 1999, Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis, Neuropharmacology, 1043
  29. Schmitz, 2015, BF-1—a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs, Eur J Pharmacol, 73
  30. Manivet, 2000, PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor, J Biol Chem, 9324
  31. Yonehara, 1999, Effect of nitric oxide on substance P release from the peripheral endings of primary afferent neurons, Neurosci Lett, 199
  32. Bonhaus, 1999, RS-127445: A selective, high affinity, orally bioavailable 5-HT2B receptor antagonist, Br J Pharmacol, 1075
  33. Terrón, 2002, Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine?, Eur J Pharmacol, 1
  34. Bennett, 2001, Neurotrophic factors: Important regulators of nociceptive function, Neuroscientist, 13
  35. Amaya, 2004, NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia, Eur J Neurosci, 2303
  36. Saldanha, 1999, Decreased CGRP, but preserved Trk A immunoreactivity in nerve fibers in inflamed human superficial temporal arteries, J Neurol Neurosurg Psychiatry, 390
  37. Price, 2005, Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: Effects on neuronal survival, neurchemial properties and TRVP1-medated neuropeptide secretion, BMC Neurosci, 4
  38. Amann, 1996, Intraplantar injection of nerve growth factor into the rat hind paw: Local edema and effects on thermal nociceptive threshold, Pain, 323
  39. Schicho, 1999, Regeneration effect of human recombinant NGF on capsaicin-lesioned sensory neurons in the adult rat, Brain Res, 60
  40. Martins, 2015, Migraine is associated with altered levels of neurotrophins, Neurosci Lett, 6
  41. Bredt, 1999, Endogenous nitric oxide synthesis: Biological functions and pathophysiology, Free Radic Res, 577
  42. Szabó, 1996, Physiological and pathophysiological roles of nitric oxide in the central nervous system, Brain Res Bull, 131
  43. Olesen, 2008, The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache, Pharmacol Ther, 157
  44. Johnson, 2003, Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation, Cephalalgia, 117
  45. Ramachandran, 2014, Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation, Cephalalgia, 136
  46. Klede, 2003, The effect of the nitric oxide synthase inhibitor N-nitro-L-arginine-methyl ester on neuropeptide-induced vasodilation and protein extravasation in human skin, J Vasc Res, 105
  47. Guldiken, 2009, Asymmetric dimethylarginine and nitric oxide levels in migraine during the interictal period, J Clin Neurosci, 672
  48. Smith, 1991, Prostaglandin and thromboxane biosynthesis, Pharmacol Ther, 153
  49. Hingtgen, 1995, Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3',5'-cyclic monophosphate transduction cascade, J Neurosci, 5411
  50. Ebersberger, 1999, Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro, Neuroscience, 901
  51. Schuh-Hofer, 2006, Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat, Headache, 276
  52. Bormann, 2000, The 'ABC' of GABA receptors, Trends Pharmacol Sci, 16
  53. Welch, 1975, Cerebrospinal fluid gamma aminobutyric acid levels in migraine, Br Med J, 516
  54. Linde, 2013, Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults, Cochrane Database Syst Rev, CD010611
  55. Guennoun, 2015, Progesterone and allopregnanolone in the central nervous system: Response to injury and implication for neuroprotection, J Steroid Biochem Mol Biol, 48
  56. Hou, 2002, Capsaicin receptor immunoreactivity in the human trigeminal ganglion, Neurosci Lett, 223
  57. Akerman, 2003, Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation, Br J Pharmacol, 718
  58. Rapoport, 2004, Intranasal medications for the treatment of migraine and cluster headache, CNS Drugs, 671
  59. Jakubowicz, 2010, Complex regional pain syndrome/reflex sympathetic dystrophy, J Pain Palliat Care Pharmacother, 160
  60. Weber, 2001, Facilitated neurogenic inflammation in complex regional pain syndrome, Pain, 251
  61. Leis, 2004, Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome, Neurosci Lett, 163
  62. Kingery, 2003, A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II, Pain, 75
  63. Staud, 2002, Peripheral and central sensitization in fibromyalgia: Pathogenetic role, Curr Pain Headache Rep, 259
  64. De, 2000, Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofacial pain syndrome, J Rheumatol, 2906
  65. Vaeroy, 1988, Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis, Pain, 21
  66. Corrigan F, Vink R, Turner RJ. Inflammation in acute CNS injury: A focus on the role of substance P. Br J Pharmacol 2015. [Epub ahead of print]. · DOI
  67. Kiani, 2015, A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy, J Res Med Sci, 359
  68. Olesen, 2004, ; BIBN 4096 BS Clinical Proof of Concept Study Group.Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine, N Engl J Med, 1104
  69. Phebus, 1997, The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs, Life Sci, 1553
  70. Norman, 1998, A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine, Cephalalgia, 407
  71. Polley, 1997, The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system, Regul Pept, 23
  72. Ashina, 2002, Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache, Expert Opin Pharmacother, 395
  73. Shepheard, 1999, Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370, Cephalalgia, 851
  74. Earl, 1999, Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine, Cephalalgia, 357
  75. Gomez-Mantilla, 2001, Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine, Cephalalgia, 727
  76. Brändli, 1996, Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater, Pain, 315
  77. Evers, 2004, Botulinum toxin A in the prophylactic treatment of migraine — a randomized, double-blind, placebo-controlled study, Cephalalgia, 838
  78. Morris, 2001, Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons, Am J Physiol Heart Circ Physiol, H2124
  79. Tugnoli, 2007, Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin, Pain, 76
  80. Liberopoulos, 2006, Could statins be useful in the treatment of patients with migraine?, Headache, 672
  81. Kim, 2007, Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model, Eur J Pharmacol, 76

Cited by

See all 162

Metadata

Authors
Malhotra, R.
Venue
Annals of Indian Academy of Neurology
Publisher
Medknow
Published
2016
Volume
19
Issue
2
Pages
175
ISSN
0972-2327 (ISSN-L)
OpenAlex
W2390524195
Cited by
162
References
3
FWCI
11.12
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.